Trial Profile
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Gabapentin Extended Release (G-ER) Tablets in the Treatment of Patients With Painful Diabetic Peripheral Neuropathy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Nov 2018
Price :
$35
*
At a glance
- Drugs Gabapentin (Primary)
- Indications Diabetic neuropathies; Neuropathic pain
- Focus Therapeutic Use
- Sponsors Assertio Therapeutics; Depomed
- 22 Jun 2007 Results have been presented.
- 09 Oct 2006 New trial record.